Needham Remains a Buy on RxSight (RXST)

In a report released today, David Saxon from Needham maintained a Buy rating on RxSight (RXSTResearch Report), with a price target of $22.00. The company’s shares closed yesterday at $12.62.

Saxon covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Cooper Co, and NuVasive. According to TipRanks, Saxon has an average return of -17.2% and a 17.39% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for RxSight with a $20.33 average price target, representing a 61.09% upside. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $24.00 price target.

See today’s best-performing stocks on TipRanks >>

RXST market cap is currently $348.7M and has a P/E ratio of -5.05.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

Read More on RXST:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More